Skip to main content

Table 18 The cost-effectiveness analysis in the 24-month period (the reversion rate)

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group C (yuan) E (%) C/E ΔC/ΔE
The treatment group 44911142.2 41.1 995812.5  
The control group 40740835.2 30 1358027.8 276179.3